BioSpace News Archive

The global Parkinson’s disease therapeutics market was valued at US$ 2.18 Bn in 2016 and is projected to register a cumulative annual growth rate of more than 10.9% from 2017 to 2025, according to a new report titled “Parkinson’s Disease Threapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025” published by Transparency Market Research

The need for reduction of errors in healthcare service and patient care delivery is a key driver for growing interest in healthcare automatic identification and data capture systems.

Cardiovascular diseases comprise disorders and conditions related to circulatory system which include heart and vascular system.

Allele Biotechnology and Pharmaceuticals, Inc. has been using mRNA as its core technology for creating cGMP-grade iPSC lines for regenerative medicine and oncology for over a decade.

Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 2,100 shares of Calithera’s common stock, at a per share exercise price of $3.45, the closing trading price on September 30, 2020.

Kyowa Kirin Co., Ltd. announced the first patient has been dosed in the pivotal Phase 2 study of zandelisib, an oral, once-daily, investigational drug-candidate selective for phosphatidylinositol 3-kinase delta in patients with indolent B-cell non-Hodgkin’s lymphoma without small lymphocytic lymphoma, lymphoplasmacytic lymphoma, and Waldenström’s macroglobulinemia in Japan.

Sierra Oncology, Inc. granted stock options to two new employees, as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.

Bristol Myers Squibb announced that the company will host a virtual Investor Event on Monday, October 12, 2020 at 8:00 a.m. EDT to discuss results from the Phase 3 True North trial evaluating Zeposia® in patients with moderate to severe ulcerative colitis, which will be presented at United European Gastroenterology Week 2020.

Humanigen, Inc. announced updates on its lenzilumab in COVID-19 development program, including written guidance received from the US Food and Drug Administration following a Type B meeting to obtain feedback on plans for an Emergency Use Authorization.

Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the completion of patient enrollment in the Phase 3 clinical trial of OTIVIDEX in Ménière’s disease. A total of 149 patients have been enrolled in the trial, exceeding the target of 142 patients. Following randomization to treatment with a single intratympanic injection of OTIVIDEX or placebo, patients ar